Researchers have found a potential association between high blood levels of PCBs and furans with an increased risk of developing non-Hodgkin lymphoma. The study analyzed blood samples from 100 healthy volunteers and 100 non-Hodgkin lymphoma patients, revealing a link between three specific molecular forms of PCBs and cancer development.
Researchers are exploring nanostructures to detect and target cancer cells, offering potential cost-effective diagnostic methods. Nanoshells can destroy tumor cells when heated with laser light, while nanoparticles combined with hormones and peptides are being tested for imaging and targeting.
Researchers investigate compounds like thalidomide, arsenic, and insecticide-derived drugs for their potential to treat solid tumors and various types of cancers. These novel approaches aim to overcome resistance to existing treatments and reduce adverse effects associated with hormonal ablation therapy.
Studies identify molecular markers that can predict clinical outcome for patients with non-small cell lung cancer treated with gefitinib. Researchers found subgroups of patients with specific biomarkers, including EGFR gene copy number and Akt activation status, have increased survival rates.
Researchers have discovered a novel bacterial protein azurin that can selectively target and kill cancer cells, while also using electric pulses to deliver a gene therapy that stimulates an immune system attack. Additionally, a small nanoparticle has been developed to reduce side effects of radiation and chemotherapy treatment.
Research suggests that smokeless oral tobacco products and medicinal nicotine products may be safer alternatives to cigarette smoking. However, studies also found that these products may not be effective in reducing smoking use and related diseases. Medicinal nicotine products appear to be a better option for smokers looking to quit.
Lung cancer researchers are exploring new approaches to prevent and treat the disease, including nicotine vaccines that can reduce tobacco dependence. Additionally, studies on chemoprevention strategies aim to identify populations at high risk for lung cancer and design effective prevention methods.
Researchers discovered that calcitriol and QW-1624-F2-2 slowed prostate cancer progression in intact mice after 14 weeks of treatment, reducing tumor burden. However, chronic treatment showed side effects, highlighting the need for further studies to understand how these agents prevent prostate cancer.
Researchers have identified compounds that can reduce cancer incidence, including thiazolidinediones for type-2 diabetes patients. Synthetic triterpenoids like CDDO-Im also show potent protection against liver tumors.
Research suggests that adding these foods to the diet can prevent or halt cancer growth. Broccoli sprouts were found to reduce Helicobacteri pylori infection and alleviate gastritis in infected individuals.
The GARDASIL vaccine has been shown to be highly effective in preventing high-grade pre-cancerous illnesses and non-invasive cervical cancers. In a larger population analysis, the vaccine prevented 99% of HPV 16 or 18-related high-grade cervical pre-cancers.
Dr. Lippman's work has uncovered new means of treating and preventing several types of cancer through his research on molecular biology and carcinogenesis. His studies have also led to the development of molecular targeted drugs for cancer prevention, including trials for high-risk populations.
The American Association for Cancer Research will honor Senator Arlen Specter for his tireless support of biomedical research funding. His leadership and collaboration have led to significant advancements in cancer care, making Pennsylvania a hub for cutting-edge research institutions.
A recent study has found that patients who are obese at age 40 and experience rapid weight gain have a higher risk of prostate cancer recurrence. The research, published by the American Association for Cancer Research, suggests that men who gained an average of three and a half pounds per year are more likely to experience biochemical ...
Researchers found a significant association between the mitochondrial DNA variant and increased breast cancer risk in African-American women, while white women carry a much higher frequency of the allele without apparent implications for breast cancer risk.
Activated vitamin D, when combined with NSAIDs, may offer a more tolerable treatment option for prostate cancer. The drug combination limits prostate cancer cell growth by targeting the same molecules attacked by NSAIDs, promoting the breakdown of prostaglandin hormones.
Researchers found that lesions stained with toluidine blue were six times more likely to become oral cancers and contained molecular alterations linked to high risk. The dye-staining lesions had characteristic molecular changes that predicted higher risk for oral cancers, even at early stages.
Scientists discover that cyclin D1, overproduced in half of all breast cancers, can disrupt BRCA1's normal role as a cancer inhibitor. Cyclin D1 interferes with BRCA1 function by occupying the same binding site on estrogen receptor alpha, negating its tumor suppressor role.
Tom Curran, a prominent cancer researcher, has been elected Fellow of the Royal Society. His work on molecular oncology and neurobiology has made significant impacts on our understanding of brain cancers and gene regulation.
A study led by Daniel W. Cramer found that high blood levels of antibodies against MUC1 protein are associated with lower incidence of ovarian cancer. These events include bone fractures and gynecological surgeries, suggesting a potential link between immune system activation and cancer protection.
Research suggests that maternal diets high in omega-3 fatty acids during pregnancy and breastfeeding may reduce the risk of breast cancer in daughters. In contrast, high consumption of omega-6 fatty acids has been linked to increased estrogen levels, which can contribute to the development of breast cancer. The study's findings support...
A large cohort study found that high consumption of processed meats was associated with a significant increase in pancreatic cancer risk. The study, which followed over 190,000 participants, suggests that chemical reactions during meat preparation may be responsible for this link.
A clinical trial conducted by Italian scientists found that green tea catechins inhibited cancer cell growth in men with high-grade prostatic intraepithelial neoplasia, leading to a 90% efficacy rate in preventing prostate cancer. The study identified Clusterin as a key mediator of the catechins' action.
Researchers have developed oncolytic viruses that can infiltrate and destroy tumor cells while leaving surrounding healthy tissue intact. These 'cancer-killing' viruses are being tested in patients with various tumor types, including melanoma, breast, head and neck, and colorectal cancer.
Scientists have developed a new compound, AMN107, that shows promise in overcoming resistance to Gleevec, a highly successful leukemia treatment. In studies, AMN107 was found to be at least 20 times more potent than Gleevec against most resistant mutants, offering a potential cure for patients with acquired drug resistance.
Researchers at UCLA isolated biomarkers from saliva that accurately predicted oral squamous cell carcinoma in 90% of cases. These biomarkers, known as salivary transcriptomes, also showed promise for detecting head and neck cancers. The study's findings suggest a potential breakthrough in early disease detection.
Scientists at Emory University have discovered that mitochondrial DNA variants are associated with a two-fold increase in prostate cancer risk and up to two-and-a-half times the risk for renal cancer. The U haplogroup, found among 9.6% of Caucasian Americans, is linked to an increased risk, particularly among those from northern and Ea...
Researchers have discovered gene portfolios that can define a patient's likelihood of developing cancers, responding to treatment, and fending off malignancies. These 'Death from Cancer Signature' portfolios provide opportunities for early identification and targeted therapies, potentially improving five-year survival rates.
Researchers have developed a novel delivery system that uses siRNA to silence the growth-promoting gene EWS-FLI1 in tumor cells, effectively inhibiting cell replication by 80%. The nanoparticles are designed to target specific tumor sites and avoid degradation, making them a promising treatment option for Ewing's sarcoma.
A portfolio of 173 genes is differentially expressed in patients with hereditary nonpolyposis colon cancer (HNPCC) treated with celecoxib, suggesting the drug may suppress colon polyp formation and early colon cancer.
A low-dose blend of celecoxib and Lipitor significantly reduces invasive and non-invasive colon adenocarcinomas by 95% in laboratory animals. The combination targets different molecular pathways to prevent colon cancer development, suggesting a promising approach for maximizing anti-cancer efficacy while minimizing toxicity.
Researchers found that men who used statins had half the risk of advanced prostate cancer and a third of the risk of metastatic or fatal prostate cancer. The study suggests statins may offer benefits for preventing invasive and metastatic prostate cancer.
A recent study found that patients taking calcium supplements had a 36 percent reduction in polyp formation, with even greater protection against non-neoplastic hyperplastic polyps. However, the protective effect diminished over time, falling to a non-significant 19 percent after 10 years.
A population-based study found that long-term NSAID use significantly reduced the risk of developing oral cancer in light to moderate smokers, with a 65% decrease observed compared to non-NSAID users. The most effective NSAIDs were those used by smokers with low pack-year tobacco consumption.
Patients who had surgery in the summer months with high vitamin D intake showed better disease-free survival rates (83% vs. 46%) and overall survival rates (72% vs. 30%) compared to those with low vitamin D intake or winter surgeries. The study suggests a potential link between vitamin D and improved cancer outcomes.
The study found that sulindac induced expression of the p21 gene, which suppressed tumor formation even in mice missing key tumor suppressor genes and fed a high-fat diet. The researchers suggest that p21 activation through sulindac offers protection against both genetic and dietary factors contributing to cancer development.
The American Association for Cancer Research has conferred international awards to world-class scientists, with recipients presenting lectures at the AACR Annual Meeting. The honorees represent leading researchers in basic research, clinical care, and prevention.
Knudson's two-hit theory explained the hereditary and sporadic forms of retinoblastoma, launching the study of tumor suppressor genes. His work has profoundly influenced cancer research, guiding countless geneticists and molecular biologists.
Randy 'Duke' Cunningham, a prostate cancer survivor, receives funding for cancer research through his committee work. Deidre Downs, Miss America 2005, continues her childhood cancer research efforts through CureSearch and her medical student program.
Nineteen undergraduate students have been awarded the AACR-Thomas J. Bardos Science Education Awards for their outstanding contributions to cancer research. The recipients will receive financial support to attend two consecutive Annual Meetings, providing them with a platform to network and learn from leading scientists.
The American Association for Cancer Research (AACR) has awarded scholarships to 103 full-time graduate, medical, or postdoctoral students and junior faculty members from underrepresented groups. The recipients will receive stipends to attend the AACR Annual Meeting and present their research papers.
The AACR Minority Scholar Awards program aims to increase minority participation in cancer research by providing opportunities for young scientists and clinicians. The program's 20th anniversary is being celebrated with a special session and gala, honoring past award recipients and recognizing the contributions of minority researchers.
Cantley's discovery of phosphoinositide 3-kinase (PI3K) revealed a new lipid produced only when cells are stimulated with growth factors or made cancerous. His work has supported the model that PI3K plays a critical role in many human cancers, and its inhibition is being explored for various diseases.
The AACR-Minorities in Cancer Research-Jane C. Wright Lectureship recognizes outstanding scientists advancing minority investigators in cancer research. Dr. Wright's pioneering work in clinical cancer chemotherapy and leadership in the field have a lasting impact on cancer research.
Researchers Elizabeth Blackburn and Janet Rowley have been awarded the Landon-AACR Prizes for Basic and Translational Cancer Research. Their work has led to a deeper understanding of telomeres, enzymes that play a role in cancer growth.
A study found that carriers of a genetic variant associated with low antioxidant levels in the blood have a significantly increased risk of developing aggressive prostate cancer. The research highlights the potential role of antioxidants such as selenium and vitamin E in preventing prostate cancer.
Researchers found celecoxib reduces prostate cancer cell growth and proliferation by targeting both COX-2 and cyclin D1. In animal models, celecoxib also reduced tumor mass and blood vessel density, suggesting a potential new therapeutic approach for treating prostate cancer.
The American Association for Cancer Research (AACR) has awarded 6 minority researchers to attend cancer conferences in 2005. The awards allowed early career scientists from underrepresented groups to attend the conferences, providing them with opportunities to share new discoveries and advance their careers.
The American Association for Cancer Research (AACR) has awarded four faculty members from Minority-Serving Institutions for their meritorious work in basic, clinical, or translational cancer research. The awardees attended special conferences focused on oncogenesis and oncogenomics.
The American Association for Cancer Research recognizes Melissa J. Parsons and G. Ruth Thomas as the first award recipients in 2005, honoring their meritorious scientific papers on cell death in oncogenesis. The AACR aims to accelerate cancer prevention and cure through research, education, and advocacy.